Eli Lilly and Company Stock News

SAN DIEGO--(BUSINESS WIRE)-- #AIinHealthcare--Creyon Bio, Inc. (“Creyon”) today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focused on the discovery, development and commercialization of novel RNA-targeted oligonucleotide (oligo) therapies for a broad range of diseases. As a part of the collaboration, Creyon will leverage its industr...

Eli Lilly and Company's orforglipron generated positive results in the phase 3 trial in type 2 diabetes patients. The results look good or better than oral semaglutide (across trials) and similar to injectable semaglutide. The importance of these LLY results cannot be understated, as this should be the first oral obesity product that can be produced at scale to satisfy global demand.

HSBC double downgraded Eli Lilly to Reduce, citing too much optimism around its new weight-loss pill, and the strength of Novo Nordisk's Ozempic brand.

Eli Lilly And Co (NYSE:LLY) stock is 1.6% lower to trade at $870.31 at last check, after a rare double downgrade from HSBC to "reduce" from "buy," and a price-target cut to $700 from $1,150.

Investors should consider trimming exposure to Eli Lilly & Co (NYSE: LLY) following a more than 20% increase in the pharma stock's price in recent weeks, says Rajesh Kumar, a senior HSBC analyst.  Lilly has long been a top performer in the pharmaceutical space as investors continue to reward its lead in weight-loss treatments.

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so.

Eli Lilly's Orforglipron shows promising Phase III results, potentially becoming a best-in-class oral GLP-1 receptor agonist for diabetes and obesity by 2026. Despite macroeconomic headwinds, Lilly's strong pipeline and market leadership in incretin analogues support a "Buy" rating for long-term investors with DCA strategy. Lilly's oncology and neuroscience sectors are progressing, with signifi...

Eli Lilly has requested Europe's drug regulator to re-examine its opinion on the company's Alzheimer's drug, the agency said on Friday.